Zhi Tong Cai Jing·2026-01-13 03:24Core Viewpoint - China Biologic Products (01177) has seen a stock increase of over 4%, currently trading at 7.09 HKD with a transaction volume of 431 million HKD. UBS reports that the management requires more time to finalize the guidance for the business development of external authorization (BD) this year [1] Group 1: Clinical Data and Product Development - The company is expected to announce clinical data results this year, including Phase I clinical data for TQB3702 in blood cancer, Phase II clinical data for TQA3334, and Phase III clinical data for lanifibranor targeting metabolic-associated fatty liver disease [1] - Management is optimistic about the inclusion prospects of VIIa in the 2025 National Medical Insurance Drug List negotiations, as only three companies have been selected for inclusion [1] Group 2: Recent Approvals and Market Impact - Penpulimab has successfully entered the medical insurance catalog for the first time, while anlotinib has been approved for expansion to first-line treatment of soft tissue sarcoma without any price reduction [1] - Yilishu benefits from an expanded reimbursement scope, enhancing its market accessibility [1] Group 3: Product Significance - The VIIa product, developed by the company's subsidiary, is the first domestically produced recombinant human coagulation factor VIIa (brand name: Anqixin), which received NMPA approval on July 3, 2025 [1] - This product breaks the long-standing monopoly of imported products, improving medication accessibility for hemophilia patients and reducing treatment costs [1]